Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #1703 on Adamis Pharmaceuticals Corp (ADMP)
THEBEASTMUGABI
09/27/18 4:22 PM
#1704 RE: H2R #1703
H2R
09/27/18 4:30 PM
#1705 RE: H2R #1703
The FDA approves Adamis Pharmaceuticals' (NASDAQ:ADMP) lower-dose version (0.15 mg) of emergency allergic reaction med Symjepi (epinephrine) for pediatric use. Novartis (NYSE:NVS) unit Sandoz will commercialize. ADMP will resume trading at 4:25 pm ET.
XenaLives
12/31/18 11:26 AM
#1731 RE: H2R #1703